Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.44 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.44 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 8/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4108405 | 1.00 | CHRNA7 (0.45) | CHRNA7KCNH2PIP4K2APIP4K2BPIP4K2C | |
| SCHEMBL4101615 | 0.89 | PIP4K2A (0.42) | CHRNA7KCNH2PIP4K2APIP4K2BPIP4K2C | |
| SCHEMBL4114354 | 0.81 | KCNH2 (0.49) | CHRNA7KCNH2PIP4K2APIP4K2BPIP4K2C | |
| SCHEMBL4114351 | 0.81 | KCNH2 (0.49) | CHRNA7KCNH2PIP4K2APIP4K2BPIP4K2C | |
| SCHEMBL4108711 | 0.81 | KCNH2 (0.49) | CHRNA7KCNH2PIP4K2APIP4K2BPIP4K2C | |
| SCHEMBL4108713 | 0.81 | KCNH2 (0.49) | CHRNA7KCNH2PIP4K2APIP4K2BPIP4K2C | |
| SCHEMBL4117768 | 0.80 | PIP4K2A (0.44) | CHRNA7KCNH2PIP4K2APIP4K2BHRH3 | |
| SCHEMBL4117772 | 0.80 | PIP4K2A (0.44) | CHRNA7KCNH2PIP4K2APIP4K2BHRH3 | |
| SCHEMBL4120169 | 0.79 | CHRNA7 (0.49) | CHRNA7KCNH2PIP4K2APIP4K2BHRH3 | |
| SCHEMBL4120175 | 0.79 | CHRNA7 (0.49) | CHRNA7KCNH2PIP4K2APIP4K2BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2604611-A1 | N-Biaryl substituted diazabicycloalkane derivatives as agonists of the alpha7 and alpha4beta2 nACh Receptor | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | claimed |
| US-20090197860-A1 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-08-06 | — | — | US | claimed |
| EP-2604611-A1 | N-Biaryl substituted diazabicycloalkane derivatives as agonists of the alpha7 and alpha4beta2 nACh Receptor | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20090197860-A1 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197860-A1 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES | BRCA1, VHL, AADAC | CHRNA7 3093/4885KCNH2 2724/4885PIP4K2A 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.